Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 9 Nov 2023 |
| Major Shareholder Announcement | 9 Nov 2023 |
| Major Shareholder Announcement | 8 Nov 2023 |
| Genmab Announces Financial Results for the First Nine Months of 2023 | 7 Nov 2023 |
| Genmab Announces Multiple Abstracts to be Presented at the 65th Annual Meeting and Exposition of the American Society of Hematology (ASH) | 2 Nov 2023 |